Acelyrin, Inc. (SLRN)

4,3700 +0,0200 (+0,46%) Börsenschluss: 04:00PM EDT

Acelyrin, Inc.

4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States
805-730-0360
https://www.acelyrin.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 135

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Shao-Lee Lin M.D., Ph.D.	Co-Founder, CEO & Director	891,59k	N/A	1967
Ms. Melanie Gloria B.S.N.	Chief Operating Officer	667,52k	N/A	1978
Mr. Ron Oyston	Chief People Officer	551,96k	N/A	1970
Mr. Gilbert M. Labrucherie J.D.	Chief Financial Officer	N/A	N/A	1972
Ms. Mina Kim	Chief Legal & Administrative Officer and Corporate Secretary	N/A	N/A	1974
Mr. Tyler Marciniak	Head of Investor Relations & Communications	N/A	N/A	N/A
Dr. Paul M. Peloso M.D., M.Sc.	Chief Medical Officer	N/A	N/A	1958
Ms. Suzy Buckhalter CPA	Senior Director of Finance & Accounting	N/A	N/A	N/A
Mr. Kenneth A. Lock	Chief Commercial Officer	N/A	N/A	1974
Dr. Shephard Mpofu M.D.	Senior Vice President of Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Corporate Governance

Acelyrin, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.